Table of Contents Table of Contents
Previous Page  24 / 812 Next Page
Information
Show Menu
Previous Page 24 / 812 Next Page
Page Background

S20

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S18–S55

use of this substance in alcohol-dependent individuals and higher

biomarkers of alcohol use.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.821

S06

Potential relationship between

inflammatory markers, neuroimaging

findings and treatment response in

depression

A. Szulc

Medical University of Warsaw, Department of Psychiatry, Pruszkow,

Poland

Pharmacological therapy in mental disorders is usually effective

in 60–70%, the treatment reaction is worsening with the disease

progression, and proper medication and early treatment regimen

choice is crucial. Research showed that specific brain changes

(structural and functional) are present in depressed patients. These

abnormalities are probably linked to neurodegeneration. There is

also an evidence that inflammation contributes to the depression

pathophysiology, and both these processes – neurodegeneration

and inflammation are related.

Novel biological markers allow us to better understand the indi-

vidual mechanisms of treatment response in depression. Recently,

several biological measures have been proposed, amongst them –

neuropsychological dysfunction, decreased GABA level in proton

magnetic resonance spectroscopy (

1

H MRS), body weight, genetic

factors andperipheral inflammatorymarkers. Latest research found

that brain changes assessedwith neuroimagingmethods (including

1

H MRS, e.g. glutamatergic system abnormalities), correlate with

peripheral inflammatory markers. Furthermore, both these factors

taken together may serve as one integrated treatment prediction

marker in depressed patients.

Disclosure of interest

The author has not supplied his declaration

of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.822

Bipolar disorders: From detection to intervention

S07

Developmental trajectories to bipolar

disorder

S. Frangou

Icahn School of Medicine at Mount Sinai, Psychiatry, New York, USA

Background

Childhood subclinical phenotypes have been infor-

mative for etiological research and as a target for preventative

interventions. Using a prospective longitudinal general population

cohort we investigated whether childhood manic symptoms pre-

dicted a diagnosis of bipolar disorder (BD) or other psychiatric

disorders by early adulthood.

Methods

Subthreshold manic symptoms at age 11 years

(

n

= 1907) and clinical outcomes by age 19 years (

n

= 1584) were

ascertained in the TRacking Adolescents’ Individual Lives Survey

(TRAILS), a prospective Dutch community cohort. We used latent

class analysis to stratify TRAILS participants at age 11 years into

distinct classes based on the pattern and severity of childhood

manic symptoms. We then determined the association between

class membership and clinical diagnoses by age 19 years.

Results

At age 11 years, we identified a normative class with

negligible symptoms (

n

= 862), a mildly symptomatic (

n

= 846)

and a highly symptomatic class (

n

= 199). The risk of BD was

moderately increased in individuals in the mildly symptomatic

class (OR = 2.65, 95% CI 1.41–5.01), and substantially increased

in the highly symptomatic class (OR = 7.08, 95% CI = 3.32–15.11).

Children in the highly symptomatic class were additionally char-

acterized by lower IQ and socioeconomic status, greater family

dysfunction and increased rates of parental psychiatric morbidity.

Class membership did not show significant associations with

depressive, anxiety and substance abuse disorders by age 19 years.

Conclusions

The results provide support to developmental mod-

els of BD, and suggest that manic symptoms in childhood may be a

marker for adult disorders and therefore potentially useful for early

identification of at risk individuals.

Disclosure of interest

The author has not supplied his declaration

of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.823

S08

Protecting the cardiometabolic health

of young people experiencing

psychosis

D. Shiers (Honorary Reader in Early Psychosis)

School of Psychological Sciences, University of Manchester, United

Kingdom

This presentation will highlight how the early phase of major men-

tal illness may provide a critical window of opportunity in which to

prevent future life-restricting and life-shortening physical comor-

bidities.

Despitemany recent advances in our understanding of severemen-

tal illnesses, those affected still lose 15–20 years of life on average

compared to the general population. Most premature deaths arise

from the same common disorders that affect the general popula-

tion such as cardiovascular disease, infections and cancers. Of these

cardiovascular diseases is now the single biggest cause, far greater

than suicide. Shockingly the mortality gap is still widening as the

reduction in CVD morbidity and mortality seen in the general pop-

ulation over the last three decades continues to elude people with

severe mental illnesses, for whom the prevalence of CVD, obesity

and diabetes are now of epidemic proportion.

And yet, much of this epidemic can be predicted. High rates of

tobacco use, physical inactivity and poor nutrition point to under-

lying health inequalities. Furthermore, initiation of antipsychotic

treatment is associated with aggressive weight gain and metabolic

disturbance from the early phase of psychosis, and yet often these

adverse effects remain unmonitored and untreated.

This presentation will argue that these potentially modifiable risk

factors provide natural targets for prevention from the onset of psy-

chosis and its treatment. Extending the early interventionparadigm

to embrace a far more holistic body & mind approach is overdue.

Disclosure of interest

The author has not supplied his declaration

of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.824

S09

Implementing the clinical standards

of the National Institute for Health

and Care Excellence (NICE) bipolar

clinical guideline

M. Tremblay

1 , 2 ,

, S . P

alin

1

1

Cheshire and Wirral Partnership NHS Foundation Trust, Mental

Health, Winsford, United Kingdom

2

Fellow of NICE (2012–2015)

Corresponding author.

In the UK, the National Institute for Health and Care Excellence

(NICE) sets standards for interventions to drive improvement in the

quality of services delivered. The actual update of clinical guidelines

remains patchy and difficult to ascertain.